Citi analyst Robyn Karnauskas opened a catalyst watch on Gilead Sciences ahead of its 4 selonsertibi data readout in Q1. The analyst sees potential upside for the shares and notes nonalcoholic steatohepatitis represents $11 of her $106 price target on Gilead. She keeps a Buy rating on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.